Patient-derived tumour models for personalized therapeutics in urological cancers

Preclinical knowledge of dysregulated pathways and potential biomarkers for urological cancers has undergone limited translation into the clinic. Moreover, the low approval rate of new anticancer drugs and the heterogeneous drug responses in patients indicate that current preclinical models do not always reflect the complexity of malignant disease. Patient-derived tumour models used in preclinical uro-oncology research include 3D culture systems, organotypic tissue slices and patient-derived xenograft models. Technological innovations have enabled major improvements in the capacity of these tumour models to reproduce the clinical complexity of urological cancers. Each type of patient-derived model has inherent advantages and limitations that can be exploited, either alone or in combination, to gather specific knowledge on clinical challenges and address unmet clinical needs. Nevertheless, few opportunities exist for patients with urological cancers to benefit from personalized therapeutic approaches. Clinical validation of experimental data is needed to facilitate the translation and implementation of preclinical knowledge into treatment decision making. In this Review, van de Merbel et al. provide a comprehensive overview of the current patient-derived tumour models in use for urological cancers and discuss their advantages and limitations, as well as their potential for personalized treatment.

Automated summary

Preclinical knowledge and potential biomarkers for urological cancers have limited translation into clinical practice. Patient-derived tumor models, including 3D culture systems and xenograft models, have improved capacity to mimic the complexity of urological cancers. Opportunities for personalized therapeutic approaches for patients with urological cancers are limited and clinical validation of preclinical data is crucial for translation into treatment decisions.